Nureca Limited has informed the Exchange regarding Appointment of as Executive Director of the company w.e.f. Jun 01, 2026.
NURECA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Nureca Limited's board meeting on May 29, 2026 approved multiple items. FY26 full-year revenue grew 28% to Rs. 1,472.10 million with net profit of Rs. 28.36 million versus a loss of Rs. 4.60 million in FY25. However, Q4 FY26 showed a net loss of Rs. 65.74 million largely due to Rs. 83.37 million fair value loss on FVTPL investments. The CFO, Mr. Naresh Gupta, resigned effective June 26, 2026 citing better career opportunities, and was replaced by Mr. Chander Kant (previously Manager Finance) from June 27, 2026. Ms. Smita Goyal was appointed as Additional Director (Whole Time Director) effective June 1, 2026, subject to shareholder approval. The board also approved re-appointment of Mr. Aryan Goyal (CEO) and Mr. Saurabh Goyal (MD) for 3-year terms, a Rs. 100 crore capex for medical devices manufacturing expansion at Derabassi, Punjab, and purchase of additional adjoining land.
The company returned to profitability in FY26 with strong revenue growth, though Q4 weakness from investment fair value losses warrants attention. The smooth internal CFO transition with no negative commentary suggests a planned handover. Multiple related-party board appointments maintain the family-controlled governance structure.